Evidence map›Paper›PMID 32527763›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2020

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?

Cole Maguire, Teresa Frohman, Scott S Zamvil, Elliot Frohman, Esther Melamed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cole MaguireFrom the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA.
Teresa FrohmanFrom the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA.
Scott S ZamvilFrom the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA.
Elliot FrohmanFrom the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA.
Esther MelamedFrom the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA. esther.melamed@austin.utexas.edu.
University of California, San Francisco · US

Funding

Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple SclerosisK08AA027837 · NIAAA · UNIVERSITY OF TEXAS AT AUSTIN · PI MELAMED, ESTHER · 2020 to 2024
$971k
NIAAA NIH HHS K08 AA027837
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsPandemicsPneumonia, ViralAntiviral AgentsCOVID-19Drug RepositioningHumansInterferonsMultiple SclerosisAntiviral AgentsInterferons

Identifiers

PMID32527763
PMCPMC7309524
OpenAlexW3035444888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.